Atrial Fibrillation and Cancer

Ludhmila Abrahao Hajjar; Silvia Moulin Ribeiro Fonseca; Theuran Inahja Vicente Machado

doi:10.3389/fcvm.2021.590768

Atrial Fibrillation and Cancer

Front Cardiovasc Med. 2021 Jul 15:8:590768. doi: 10.3389/fcvm.2021.590768. eCollection 2021.

Authors

Ludhmila Abrahao Hajjar¹, Silvia Moulin Ribeiro Fonseca¹, Theuran Inahja Vicente Machado¹

Affiliation

¹ Cancer Institute, University of São Paulo, São Paulo, Brazil.

Abstract

Cancer patients have a higher risk of atrial fibrillation (AF) than general population, the pathophysiology mechanisms involves the pro inflammatory status of immune system in these patients and the exacerbated inflammatory response to cancer treatment and surgeries. Adequate management and prophylaxis for its occurrence are important and reduce morbidity and mortality in this population. There is a challenge in AF related to cancer to predict thromboembolic and bleeding risk in these patients, once standard stroke and hemorrhagic prediction scores are not validated for them. It is used CHA2DS2-VASc and HAS-BLED scores, the same as used in general population. In this review, we demonstrate correlated mechanisms to occurrence AF in cancer patients as well as therapeutic challenges in this population.

Keywords: anticoagulation; atrial fibrillation; cancer; cardiotoxicity; drug-drug interaction.

Publication types

Review